GSK hit with EU Court ruling over ‘pay-for-delay’ drug case
The ruling harks back to the CMA’s 2016 case that found GlaxoSmithKline had agreed to make payments totalling over £50 million to other generic suppliers of paroxetine.
Read More
Tag: paroxetine
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
